Pharmaceutical company Aradigm Corporation (NASDAQ:ARDM) disclosed on Friday the addition of Theresa Matkovits PhD to the board's audit committee and the nominating and corporate governance committee.
Currently, Dr Matkovits serves as the chief operating officer of ContraVir Pharmaceuticals as well as as a member of the board director of BioSurplus.
Most recently, Dr Matkovits has worked as Chief Operating Officer as well as Executive Vice President, Head of Drug Development at ContraVir.
Previously, Dr Matkovits was employed as the Research and Development Programme Leader at NPS Pharmaceuticals (NPS), vice president, Innovation Leader for Infectious Disease at The Medicines Company, as well as executive director, head of Strategic Planning and Operations for Novartis.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial